Target intelligence / Profile preview

Adenylate cyclase pathway downstream of dopamine receptors

Molecular classification
Signaling pathway, G protein-coupled receptor signaling
01

Overview

The adenylate cyclase pathway downstream of dopamine receptors is a fundamental signaling mechanism in the brain that translates extracellular dopamine signals into intracellular responses (Beaulieu & Gainetdinov, 2011). This pathway is bifurcated based on the type of dopamine receptor activated: D1-like receptors (D1 and D5) couple to stimulatory G-proteins (Gs/olf) to activate adenylate cyclase, increasing the production of the second messenger cyclic AMP (cAMP) (Neve et al., 2004). Conversely, D2-like receptors (D2, D3, and D4) couple to inhibitory G-proteins (Gi/o) to suppress adenylate cyclase activity and reduce cAMP levels (Missale et al., 1998). These fluctuations in cAMP regulate protein kinase A (PKA) activity, which in turn modulates various downstream targets, including ion channels, transcription factors like CREB, and the phosphoprotein DARPP-32 (Greengard, 2001). This signaling cascade is vital for motor control, motivation, and cognitive functions, and its dysfunction is a hallmark of major neurological and psychiatric conditions such as Parkinson's disease and schizophrenia (StatPearls, 2023). Therapeutic strategies often focus on using dopamine receptor ligands to restore balance within this pathway by either augmenting or inhibiting the production of cAMP.

Other names
Dopamine-mediated cAMP signaling pathwayDopaminergic adenylate cyclase cascadeD1/D2-adenylate cyclase signaling
02

Mechanism of action

Modulation of intracellular cyclic AMP (cAMP) levels through the activation or inhibition of adenylate cyclase by G-protein coupled dopamine receptors (Beaulieu & Gainetdinov, 2011).

03

Biological functions

Signal transductionNeuromodulationRegulation of second messenger systemsSynaptic plasticity
04

Disease associations

Parkinson's diseaseSchizophreniaSubstance use disorderAttention deficit hyperactivity disorder (ADHD)Bipolar disorder
05

Safety considerations

Extrapyramidal symptoms (EPS)Tardive dyskinesiaHyperprolactinemiaNeuroleptic malignant syndromeOrthostatic hypotension
06

Interacting drugs

Apomorphine

5 more in the full profile.

07

Biomarkers

Intracellular cAMP levelsPhosphorylated DARPP-32 (p-DARPP-32)Dopamine receptor occupancy (measured via PET/SPECT)Cerebrospinal fluid Homovanillic acid (HVA) levels

Beyond the preview

Go deeper on Adenylate cyclase pathway downstream of dopamine receptors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adenylate cyclase pathway downstream of dopamine receptors.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call